2Curex

20/05/2025

Cancer Treatment Just Got Personal.

Today, 2cureX ships its first IndiTreat® test kit—directly to a patient.

This is more than a delivery.
It’s the launch of Operation Twin Code—a bold move to speed up cancer care and put patients in control.

What’s IndiTreat®?
A revolutionary test that uses your own tumour sample to find out which treatments will work before you start them.
No guesswork. Just answers.

Launched under the name “Echoes from the North,” this marks the start of a powerful collaboration between our Swedish and Danish teams—bringing faster, personalised oncology to the front line.

CEO Nathaniel Hutley:
“This is a historic moment. We’re proving that precision oncology can—and must—move faster.”

This is just the beginning.
More updates. More innovation.
Cancer care, reimagined.

26/03/2025

Did you know there are over 300 chemotherapy drugs approved in the EU? That’s a lot of choices. We help find the right one for you.

We test chemotherapy drugs and combinations on your tumor outside your body – so you can take the one that works best.

Get in touch to find out more +447765141346

2cureX is pioneering the use of functional drug sensitivity testing to improve the outcome of cancer treatments.

25/03/2025

📢 2cureX Publishes Interim Report for H2 2024

We are pleased to share our latest interim report for the second half of 2024, marking a transformative period for 2cureX. This year, we underwent significant strategic restructuring, splitting into two entities:

🔹 2cureX AB (Publicly Listed) – Focused on a Direct-to-Patient commercial approach and potential acquisitions.
🔹 2cureX A/S (Privately Held) – Leading product development and regulatory advancements, including CE-IVDR certification.

🚀 Under the leadership of our new CEO, Dan Honeywell, 2cureX is committed to accelerating growth and expanding its impact in Precision Oncology.

📊 Financial Highlights:
💰 Cash position: MSEK 5.1 (vs. MSEK 1.5 in 2023)
📉 Result before tax: -3 249 KSEK (-1 225 KSEK)
📈 New investments expected in 2025 to drive our strategy forward.

Our commitment remains strong – to revolutionize cancer treatment decisions through IndiTreat®, providing oncologists with critical insights for personalized care.

🔗 Read the full report here: www.2curex.se

24/03/2025

🔬 Revolutionizing Cancer Treatment with IndiTreat® 🔬

Imagine a world where cancer treatment is personalized to your tumor—where doctors can test multiple drugs on a replica of your tumor before starting treatment. IndiTreat® makes this possible!

✅ How? It creates 3D microtumors from a patient’s biopsy, replicating real tumor behavior.
✅ Why does it matter? It helps doctors predict which treatment will work best for each patient.
✅ The impact? IndiTreat® is already CE-marked and shaping the future of cancer care.

With ongoing advancements, the next step is bringing this technology to hospitals—making personalized cancer treatment more accessible than ever.

💡 Learn more: 👉 www.inditreat.com

📌 Tag someone who needs to know about this breakthrough!

By resolving the blind spots in traditional methods such as biomarker testing, functional drug sensitivity testing now offers personalised treatment decisions for all patients. Join us. Make the best possible decision for all your patients. Be the Change.